NLRP3 and hepatocellular carcinoma: Anisodamine treatment significantly increases INF-γ and IL-27 levels and decreases TNF-α and IL-4 levels by inhibiting NLRP3, significantly suppressing HCC cell growth (Li et al., 2020).